{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:58:43Z","timestamp":1787241523162,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.neuropharm.2013.10.014","type":"journal-article","created":{"date-parts":[[2013,10,19]],"date-time":"2013-10-19T10:31:02Z","timestamp":1382178662000},"page":"334-341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor"],"prefix":"10.1016","volume":"77","author":[{"given":"M.J.","family":"Bonif\u00e1cio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Sutcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Torr\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.C.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Soares-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2013.10.014_bib1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1471-4159.1992.tb08907.x","article-title":"Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592","volume":"59","author":"Acquas","year":"1992","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40262-012-0024-7","article-title":"Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor","volume":"52","author":"Almeida","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1527-3458.2007.00020.x","article-title":"Catechol-O-methyltransferase and its inhibitors in Parkinson's disease","volume":"13","author":"Bonif\u00e1cio","year":"2007","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1471-4159.2005.03519.x","article-title":"Limited regulation of somatodendritic dopamine release by voltage-sensitive Ca channels contrasted with strong regulation of axonal dopamine release","volume":"96","author":"Chen","year":"2006","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib5","doi-asserted-by":"crossref","first-page":"7841","DOI":"10.1523\/JNEUROSCI.21-19-07841.2001","article-title":"Novel Ca2+ dependence and time course of somatodendritic dopamine release: substantia nigra versus striatum","volume":"21","author":"Chen","year":"2001","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s002280050068","article-title":"Multiple-dose clinical pharmacology of the catechol-O-methyl- transferase inhibitor tolcapone in elderly subjects","volume":"50","author":"Dingemanse","year":"1996","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0021-9258(18)74965-X","article-title":"Spectrophotometric studies: II. Preparations from washed blood cells; nitric oxide hemoglobin and sulfhemoglobin","volume":"112","author":"Drabkin","year":"1935","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/pr.56.3.1","article-title":"Catecholamine metabolism: a contemporary view with implications for physiology and medicine","volume":"56","author":"Eisenhofer","year":"2004","journal-title":"Pharmacol. Rev."},{"issue":"S1","key":"10.1016\/j.neuropharm.2013.10.014_bib9","first-page":"S155","article-title":"Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics, motor response, and erythrocyte-COMT activity in Parkinson's patients co-administered with levodopa\/dopa-decarboxylase inhibitor","volume":"28","author":"Ferreira","year":"2013","journal-title":"Mov. Disord."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2013.10.014_bib10","article-title":"Effect of opicapone single-dose regimens on levodopa pharmacokinetics, motor response, and erythrocyte-COMT activity in Parkinson's patients co-administered with levodopa\/dopa-decarboxylase inhibitor","volume":"11","author":"Ferreira","year":"2013","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib11","first-page":"S118","article-title":"The design of a double-blind, placebo- and active-controlled, multi-national phase-III trial in patients with Parkinson's disease and end-of-dose motor fluctuations: opicapone superiority vs. placebo and non-inferiority vs. entacapone","volume":"27","author":"Ferreira","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s007020170087","article-title":"The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA\/carbidopa treated rats","volume":"108","author":"Gerlach","year":"2001","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0773.1999.tb02014.x","article-title":"Microdialysis studies on the action of tolcapone on pharmacologically- elevated extracellular dopamine levels in conscious rats","volume":"85","author":"Huotari","year":"1999","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/B978-0-12-381326-8.00009-0","article-title":"Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease","volume":"95","author":"Kaakkola","year":"2010","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib15","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1021\/jm1001524","article-title":"Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase","volume":"53","author":"Kiss","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib16","first-page":"S127","article-title":"The design of a double-blind, placebo-controlled, multi-national phase-III trial in patients with Parkinson's disease and end-of-dose motor fluctuations: opicapone superiority vs. placebo","volume":"27","author":"Lees","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/B978-0-12-381326-8.00008-9","article-title":"Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of L-dopa treatment","volume":"95","author":"Marin","year":"2010","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib18","series-title":"Primate Brain Maps: Structure of the Macaque Brain","year":"2000"},{"key":"10.1016\/j.neuropharm.2013.10.014_bib19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1353-8020(02)00016-0","article-title":"Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats","volume":"9","author":"Napolitano","year":"2003","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-381326-8.00005-3","article-title":"Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors","volume":"95","author":"Nissinen","year":"2010","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/jcbfm.2010.58","article-title":"Microdialysis with radiometric monitoring of L-[beta-11C]DOPA to assess dopaminergic metabolism: effect of inhibitors of L-amino acid decarboxylase, monoamine oxidase, and catechol-O-methyltransferase on rat striatal dialysate","volume":"31","author":"Okada","year":"2011","journal-title":"J.\u00a0Cereb. Blood Flow Metab."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib22","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1212\/WNL.62.1_suppl_1.S72","article-title":"COMT inhibitors in Parkinson's disease: can they prevent and\/or reverse levodopa-induced motor complications?","volume":"62","author":"Olanow","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.10.014_bib23","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jcc.22926","article-title":"Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations","volume":"33","author":"Palma","year":"2012","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib24","series-title":"Emerging Drugs and Targets for Parkinson's Disease","first-page":"83","article-title":"Catechol-O-methyltransferase inhibitors: present problems and relevance of the new ones","author":"Palma","year":"2013"},{"key":"10.1016\/j.neuropharm.2013.10.014_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000068730","article-title":"BIA 3-202, a novel catechol-o-methyltransferase inhibitor, reduces the peripheral o-methylation of L-DOPA and enhances its availability to the brain","volume":"68","author":"Parada","year":"2003","journal-title":"Pharmacology"},{"key":"10.1016\/j.neuropharm.2013.10.014_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/syn.10049","article-title":"Time window of autoreceptor-mediated inhibition of limbic and striatal dopamine release","volume":"44","author":"Phillips","year":"2002","journal-title":"Synapse"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2013.10.014_bib27","article-title":"Effect of opicapone and entacapone on levodopa pharmacokinetics when administered with immediate release 100\/25 mg levodopa\/carbidopa in healthy subjects","volume":"28","author":"Rocha","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib28","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/bcp.12081","article-title":"Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple-dose administration in healthy subjects","volume":"76, Jan 21","author":"Rocha","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib29","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1097\/NRL.0b013e31823966e3","article-title":"Continuous dopaminergic stimulation: clinical aspects and experimental bases","volume":"17","author":"Rodriguez-Oroz","year":"2011","journal-title":"Neurologist"},{"key":"10.1016\/j.neuropharm.2013.10.014_bib30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s002280050657","article-title":"Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition","volume":"55","author":"Rouru","year":"1999","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/jnnp-2011-301205","article-title":"Molecular pathogenesis of Parkinson's disease: update","volume":"83","author":"Saiki","year":"2012","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.10.014_bib32","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/mds.23732","article-title":"Etiology and pathogenesis of Parkinson's disease","volume":"26","author":"Schapira","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev-pathol-011110-130242","article-title":"Parkinson's disease: genetics and pathogenesis","volume":"6","author":"Shulman","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0006-8993(99)01063-X","article-title":"Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase","volume":"821","author":"Vieira-Coelho","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2013.10.014_bib35","doi-asserted-by":"crossref","first-page":"10196","DOI":"10.1523\/JNEUROSCI.0665-07.2007","article-title":"Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum","volume":"27","author":"Yavich","year":"2007","journal-title":"J.\u00a0Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813004887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813004887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T13:08:02Z","timestamp":1646831282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390813004887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":35,"alternative-id":["S0028390813004887"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.10.014","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}